2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120452
    AZD-8165 1201686-72-7 98%
    AZD-8165 is a highly selective neutral thrombin inhibitor. AZD-8165 is promising for research of cardiovascular diseases such as hypertension and heart failure.
    AZD-8165
  • HY-120455
    PD 125967 128139-14-0 98%
    PD 125967 is an oligopeptide renin inhibitor. PD 125967 can be used to low blood pressure.
    PD 125967
  • HY-120485
    Raxofelast 128232-14-4 98%
    Raxofelast (IRFI-016) is an antioxidant agent in various models of ischemia-reperfusion injury. Raxofelast has antiproliferative activity in H2O2-stimulated rat aortic smooth muscle cells. Raxofelast attenuates the activation of mitogen-activating protein kinase (MAPK), ERK kinase 1, 2 (MEK1,2) and protein kinase C (PKC) without affecting Ras expression.
    Raxofelast
  • HY-120491
    L 722151 122841-09-2 98%
    L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy.
    L 722151
  • HY-120540
    BMS-182264 127749-54-6 98%
    BMS-182264 is a highly selective ATP-sensitive potassium channel agonist. BMS-182264 promotes potassium efflux and membrane hyperpolarization to induce smooth muscle relaxation and vasodilation. BMS-182264 is promising for research of cardiovascular diseases such as hypertension and myocardial ischemia.
    BMS-182264
  • HY-120554
    RWJ 29009 143164-10-7 98%
    RWJ 29009 is a highly selective ATP-sensitive potassium channel agonist. RWJ 29009 activates potassium channel in vascular smooth muscle cells, promoting potassium efflux and membrane hyperpolarization to induce coronary and peripheral vasodilation. RWJ 29009 is promising for research of cardiovascular diseases such as acute myocardial ischemia and hypertension.
    RWJ 29009
  • HY-120563
    LY135305 123199-75-7 98%
    LY 135305 is a thrombin activation inhibitor. LY 135305 inhibits spontaneous metastasis and increases animal survival.
    LY135305
  • HY-120577
    BA 41899 166020-57-1 98%
    BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF).
    BA 41899
  • HY-120611
    BMS-960 free base 1265321-86-5 98%
    BMS-960 free base is a potent and selective S1P1 receptor agonist containing isoxazole, which can be used in the research of immune diseases and vascular diseases.
    BMS-960 free base
  • HY-120612
    BMS-884775 1557206-59-3 98%
    BMS-884775 is a selective and orally active P2Y1 antagonist with an IC50 of 0.1 nM for the human P2Y1 receptor. BMS-884775 has a similar efficacy in preventing arterial thrombosis to Clopidogrel (HY-15283) and Prasugrel (HY-15284), but treatment with BMS-884775 results in shorter bleeding time and lower bleeding risk. BMS-884775 can be used in research related to antiplatelet and arterial thrombosis-associated diseases.
    BMS-884775
  • HY-120648
    CAY 10434 769917-29-5 98%
    CAY 10434 is a potent CYP4A hydroxylase inhibitor. CAY 10434 improves contractile response to angiotensin II with the maximal contractile response (Emax) 6764 mg.
    CAY 10434
  • HY-120673
    SQ 32970 122280-12-0 98%
    SQ 32970 is a tripeptidic renin inhibitor. SQ 32970 potently inhibits endothia protease.
    SQ 32970
  • HY-120694
    ML165 1355454-05-5 98%
    ML165 (RUC-2) is an aIIbb3 receptor antagonist. ML165 has orthosteric inhibition effect at the RGD binding domain. ML165 inhibits platelet adhesion to fibrinogen, and inhibits platelet aggregation (IC50: 96 nM).
    ML165
  • HY-120774
    GS-462808 1354198-41-6 98%
    GS-462808 is an oral active late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with the IC50 of 1.33 μM. GS-462808 can be used for study of arrhythmia.
    GS-462808
  • HY-120776
    SC-51316 133690-62-7 98%
    SC-51316 is an oral active angiotensin II receptor antagonist with the IC50 values of 3.6 and 5.1 nM in rat adrenal cortical and rat uterine membrane, respectively. SC-51316 shows antihypertensive activity in vivo and in vitro.
    SC-51316
  • HY-120816
    WU-07047 1702378-78-6 98%
    WU-07047, a simplified analog of YM-254890 (HY-111557), is a selective Gαq/11 inhibitor. WU-07047 can inhibit nucleotide exchange.
    WU-07047
  • HY-120818
    TRPC3/6-IN-3 1366234-01-6 98%
    TRPC3/6-IN-3 is a selective TRPC3/6 blocker. TRPC3/6-IN-3 can be used for the research of cardiovascular disease.
    TRPC3/6-IN-3
  • HY-120829
    Bisoprolol fumarate 105878-43-1 98%
    Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol fumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
    Bisoprolol fumarate
  • HY-120917
    BRD1172 1597438-86-2 98%
    BRD1172 (ML320) is a selectivity GSK3β inhibitor with an IC50 of 24 nM for GSK3β over CDK5. BRD1172 significantly inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells, and relieves negative regulation by GSK3β on β-catenin degradation and TCF/LEF promoter activities. BRD1172 can be used for Alzheimer’s disease, cardiac hypertrophy and cancers research.
    BRD1172
  • HY-120941
    LASSBio-1359 1396397-19-5 98%
    LASSBio-1359 is an adenosine A2A receptor agonist with vasodilatory and anti-inflammatory activities.
    LASSBio-1359
Cat. No. Product Name / Synonyms Application Reactivity